[Question] France — has anyone got a straight answer on telehealth
Question in the title, detail here: France — has anyone got a straight answer on telehealth.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
if a clinic will not name the facility, that is your answer
ask which facility, then ask for their testing
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
What concentration is on the label, and does it match what you were expecting?
shortage status changes and the whole arrangement changes with it
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
a telehealth intake that asks nothing has told you what it is
the pharmacy and the prescriber are two separate questions
Was there potency testing on the finished preparation, or only on the starting material?
the label on a compounded vial is a legal document, read it
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Agreed.
burned_once_twice is right about the concentration trap. It breaks arithmetic that has been reliable for months.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
ask what the beyond-use date is based on
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
- 1The shortage list is the legal hinge: the permissions that allow certain…9 comments in this branch · started by u/clara_danquah